-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 10, Ascletis announced that the company has submitted a US clinical trial application (IND) for ASC61, an oral PD-L1 small molecule inhibitor developed by itself, for the treatment of advanced solid tumors
ASC61 is a potent and highly selective oral PD-L1 small molecule inhibitor that blocks the PD-1/PD-L1 interaction by inducing the formation and endocytosis of PD-L1 dimers
Compared with PD-1/PD-L1 antibody injections, oral PD-L1 inhibitor ASC61 has the following advantages: (1) convenient administration, no need to go to the hospital for injection drugs; (2) combined with other oral antitumor drugs Form an all-oral treatment regimen; and (3) be able to adjust the dosage in a timely manner to better manage immune-related adverse events
Note: The original text has been deleted